medigraphic.com
Colegio de Medicina Interna de México.

2017, Number 6

<< Back Next >>

Med Int Mex 2017; 33 (6)

Role of spironolactone in the treatment of resistant hypertension

Solache-Ortiz G, Díaz-Barreiro LA, Cadena-Loces MG, Uribe-Miranda AV, Aldrete-Velasco J, Rodríguez-García JA

Language: Spanish
References: 24
Page: 797-808
PDF size: 594.99 Kb.


ABSTRACT

This article provides useful tools for the diagnosis and differential diagnosis of resistant hypertension. Here, we refer the recommendations of the main international guidelines of management respect to the target goals of the blood pressure, the failure of triple therapy in a large percentage of patients and the factors for the rational choice of the fourth agent for the institution of a quadruple therapy. This choice is based on the ability of spironolactone, antagonist of aldosterone receptors, to inhibit the deleterious effects of aldosterone that difficult the control of blood pressure and increase the cardiovascular risk in a high percentage of patients.


REFERENCES

  1. Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a metaanalysis of randomized and nonrandomized studies. Am J Hypert 2015;28(11):1376-85.

  2. Sternlicht H, Bakris GL. Spironolactone for resistant hypertension: hard to resist? Lancet 2015;386(10008):2032-4.

  3. Guo H, Xiao Q. Clinical efficacy of spironolactone for resistant hypertension: a meta-analysis from randomized controlled clinical trials. Int J Clin Exp Med 2015;8(5):7270-8.

  4. Mondaca D, Araos P, Yáñez C, et al. Hidroclorotiazida y espironolactona reducen la hipertrofia de la pared aórtica en la hipertensión arterial experimental. Rev Chil Cardiol 2011;30:52-8.

  5. Santamaría R, Gorostidi M. Hipertensión arterial secundaria: cuándo y cómo debe investigarse. NefroPlus 2015;7(1):11-21.

  6. Rossi GP, Seccia TM, Maniero C, Pessina AC. Drug-related hypertension and resistance to antihypertensive treatment: a call for action. J Hypertens 2011;29(12):2295-309.

  7. Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015;36:2686-95.

  8. Alonso J. Hipertensión arterial resistente o refractaria. Rev Urug Cardiol 2012;27:431-42.

  9. Mancia G, Fagard R, Narkiewicz K, et al; Grupo de Trabajo para el manejo de la hipertensión arterial de la Sociedad Europea de Hipertensión (ESH) y la Sociedad Europea de Cardiología (ESC). Guía de práctica clínica de la ESH/ESC para el manejo de la hipertensión arterial (2013). Hipertens Riesgo Vasc 2013;30(Supl 3):4-91.

  10. National Institute for Health and Clinical Excellence (NICE). NICE clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. NICE, London, 2011.

  11. James, PA, Oparil S, Carter BL, et al. JNC 8-2014. Directriz basada en la evidencia para el manejo de la HTA en adultos; informe de los miembros del panel nombrado miembro del Comité Octavo Nacional Mixto (JNC 8)-2014. JAMA 2014;311(5):507-20.

  12. Weber MA, Schiffrin EL, White WB, et al. Clinical practice guidelines for the management of hypertension in the community: a statement by the American Society of Hypertension and the International Society of Hypertension. J Clin Hypertens (Greenwich) 2014;16(1):14-26.

  13. Armario-García P, Hernández del Rey R. Hipertensión arterial refractaria. Hipertensión (Madr) 2006;23(6):184-94.

  14. Waisman G. Hipertensión arterial resistente. Rev Fed Arg Cardiol 2013;42(3):170-3.

  15. Sica DA. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. MDCVJ 2015;XI(4):235-9.

  16. Struthers AD, MacDonald TM. Review of aldosterone: and angiotensin II-induced target organ damage and prevention. Cardiovasc Res 2004;61:663-70.

  17. Williams GH. Aldosterone biosynthesis, regulation, and classical mechanism of action. Heart Fail Rev 2005;10(1):7- 13.

  18. Oliveras A, Armario P, Clarà A, et al. Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study, a randomized controlled trial. J Hypert 2016;34:1863-71.

  19. University of Alberta, Departments of Computing Science & Biological Sciences; The Metabolomics Innovation Centre, DrugBank. Spironolactone. Disponible: https://www.drugbank. ca/drugs/DB00421; consultado: febrero 12, 2016.

  20. Kaysin A, Mounsey A. Resistant hypertension? Time to consider this fourth-line drug. J Family Practice 2016;65(4):266-8.

  21. Vaclavık J, Sedlak R, Jarkovsky J, et al. Effect of spironolactone in resistant arterial hypertension: a randomized, double-blind, placebo-controlled trial (ASPIRANT-EXT). Medicine 2014; 93 (27); doi: 10.1097/MD.0000000000000162.

  22. Andrade-Ezequiel DG, Baumgratz-De Paula R, Moraes- Lovisi JC, et al. Espironolactona reduz a pressão arterial e a albuminúria de hipertensos obesos com síndrome metabólica. J Bras Nefrol 2013;35(1):69-72.

  23. Ni X, Zhang J, Zhang P, et al. Effects of spironolactone on dialysis patients with refractory hypertension: a randomized controlled study. J Clin Hypertens (Greenwich) 2014;16:658-63.

  24. Williams B, MacDonald TM, Morant S, et al, for The British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015;386:2059-68.




2020     |     www.medigraphic.com